The use of genomics and pathway analysis in our understanding and prediction of clinical renal transplant injury

Transplantation

Volumn 100, Issue 7, 2016, Pages 1405-1414

  Menon, Madhav C ^a   Keung, Karen L ^b   Murphy, Barbara ^a   O'Connell, Philip J ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTOME; BIOLOGICAL MARKER;

ACUTE GRAFT REJECTION; ACUTE KIDNEY FAILURE; GENETIC TRANSCRIPTION; GENOMICS; GRAFT FAILURE; HUMAN; IMMUNOLOGICAL TOLERANCE; KIDNEY ALLOGRAFT; KIDNEY TRANSPLANTATION; METABOLOMICS; NONHUMAN; PATHOGENESIS; PREDICTION; PRIORITY JOURNAL; PROTEOMICS; REVIEW; ACUTE KIDNEY INJURY; ALLOGRAFT; ANIMAL; GENETIC EPIGENESIS; GENETICS; GRAFT REJECTION; HUMAN GENOME; KIDNEY; PATHOLOGY; PHENOTYPE; RENAL INSUFFICIENCY;

ACUTE KIDNEY INJURY; ALLOGRAFTS; ANIMALS; BIOMARKERS; EPIGENESIS, GENETIC; GENOME, HUMAN; GENOMICS; GRAFT REJECTION; HUMANS; KIDNEY; KIDNEY TRANSPLANTATION; METABOLOMICS; PHENOTYPE; PROTEOMICS; RENAL INSUFFICIENCY; TRANSCRIPTION, GENETIC; TRANSCRIPTOME;

EID: 84944339267     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000000943     Document Type: Review

References (115)

1. Akalin E, Murphy B. Gene polymorphisms and transplantation. Curr Opin Immunol. 2001;13:572-576.
2. Gautreaux MD, Freedman BI. Genotypic variation and outcomes in kidney transplantation: donor and recipient effects. Kidney Int. 2013;84: 431-433.
3. Akalin E, O'Connell PJ. Genomics of chronic allograft injury. Kidney Int Suppl. 2010;119:S33-S37.
4. Ying L, Sarwal M. In praise of arrays. Pediatr Nephrol. 2009;24: 1643-1659; quiz 1655, 1659.
5. Akalin E, Hendrix RC, Polavarapu RG, et al. Gene expression analysis in human renal allograft biopsy samples using high-density oligoarray technology. Transplantation. 2001;72:948-953.
6. Furness PN, Taub N, Assmann KJ, et al. International variation in histologic grading is large, and persistent feedback does not improve reproducibility. Am J Surg Pathol. 2003;27:805-810.
7. Reeve J, Sellares J, Mengel M, et al. Molecular diagnosis of T cell-mediated rejection in human kidney transplant biopsies. Am J Transplant. 2013;13:645-655.
8. Reeve J, Einecke G, Mengel M, et al. Diagnosing rejection in renal transplants: A comparison of molecular-and histopathology-based approaches. Am J Transplant. 2009;9:1802-1810.
9. SarwalM, Chua MS, Kambham N, et al. Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. N Engl J Med. 2003;349:125-138.
10. Park W, Griffin M, Grande JP, et al. Molecular evidence of injury and inflammation in normal and fibrotic renal allografts one year posttransplant. Transplantation. 2007;83:1466-1476.
11. Scherer A, Krause A, Walker JR, et al. Early prognosis of the development of renal chronic allograft rejection by gene expression profiling of human protocol biopsies. Transplantation. 2003;75:1323-1330.
12. Willis JC, Lord GM. Immune biomarkers: The promises and pitfalls of personalized medicine. Nat Rev Immunol. 2015;15:323-329.
13. Baek D, Villen J, Shin C, et al. The impact of microRNAs on protein output. Nature. 2008;455:64-71.
14. Wilflingseder J, Regele H, Perco P, et al. miRNA profiling discriminates types of rejection and injury in human renal allografts. Transplantation. 2013;95:835-841.
15. Anglicheau D, Sharma VK, Ding R, et al. MicroRNA expression profiles predictive of human renal allograft status. Proc Natl Acad Sci U S A. 2009;106:5330-5335.
16. Ben-Dov IZ, Muthukumar T, Morozov P, et al. MicroRNA sequence profiles of human kidney allografts with or without tubulointerstitial fibrosis. Transplantation. 2012;94:1086-1094.
17. Susztak K. Understanding the epigenetic syntax for the genetic alphabet in the kidney. J Am Soc Nephrol. 2014;25:10-17.
18. Strehlau J, PavlakisM, LipmanM, et al. Quantitative detection of immune activation transcripts as a diagnostic tool in kidney transplantation. Proc. Natl. Acad. Sci. U. S. A. 1997;94:695-700.
19. Sharma VK, Bologa RM, Li B, et al. Molecular executors of cell death-differential intrarenal expression of Fas ligand, Fas, granzyme B, and perforin during acute and/or chronic rejection of human renal allografts. Transplantation. 1996;62:1860-1866.
20. Wang Z, Gerstein M, Snyder M. RNA-Seq: A revolutionary tool for transcriptomics. Nat Rev Genet. 2009;10:57-63.
21. Geiss GK, Bumgarner RE, Birditt B, et al. Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotech. 2008;26:317-325.
22. Shannon CP, Balshaw R, Ng RT, et al. Two-stage, in silico deconvolution of the lymphocyte compartment of the peripheral whole blood transcriptome in the context of acute kidney allograft rejection. PLoS One. 2014;9:e95244.
23. Oghumu S, Bracewell A, Nori U, et al. Acute pyelonephritis in renal allografts: A new role for microRNAs Transplantation. 2014;97:559-568.
24. Suthanthiran M, Strom TB. Renal transplantation. N Engl J Med. 1994; 331:365-376.
25. Nankivell BJ, Alexander SI. Rejection of the kidney allograft. N Engl J Med. 2010;363:1451-1462.
26. Halloran PF. T cell-mediated rejection of kidney transplants: A personal viewpoint. Am J Transplant. 2010;10:1126-1134.
27. Racusen LC, Haas M. Antibody-mediated rejection in renal allografts: lessons from pathology. Clin J Am Soc Nephrol. 2006;1:415-420.
28. Rush DN, Henry SF, Jeffery JR, et al. Histological findings in early routine biopsies of stable renal allograft recipients. Transplantation. 1994;57: 208-211.
29. Seron D, Moreso F, Bover J, et al. Early protocol renal allograft biopsies and graft outcome. Kidney Int. 1997;51:310-316.
30. El Ters M, Grande JP, Keddis MT, et al. Kidney allograft survival after acute rejection, the value of follow-up biopsies. Am J Transplant. 2013; 13:2334-2341.
31. Kee TY, Chapman JR, O'Connell PJ, et al. Treatment of subclinical rejection diagnosed by protocol biopsy of kidney transplants. Transplantation. 2006;82:36-42.
32. Nankivell BJ, Borrows RJ, FungCL, et al. Natural history, risk factors, and impact of subclinical rejection in kidney transplantation. Transplantation. 2004;78:242-249.
33. Reeve J, Halloran PF, Kaplan B. Common errors in the implementation and interpretation of microarray studies. Transplantation. 2015;99: 470-475.
34. Flechner SM, Kurian SM, Head SR, et al. Kidney transplant rejection and tissue injury by gene profiling of biopsies and peripheral blood lymphocytes. Am J Transplant. 2004;4:1475-1489.
35. de Freitas DG, Sellares J, Mengel M, et al. The nature of biopsies with "borderline rejection" and prospects for eliminating this category. Am J Transplant. 2012;12:191-201.
36. Sellares J, Reeve J, Loupy A, et al. Molecular diagnosis of antibodymediated rejection in human kidney transplants. Am J Transplant. 2013;13:971-983.
37. Famulski KS, de Freitas DG, Kreepala C, et al. Molecular phenotypes of acute kidney injury in kidney transplants. J Am Soc Nephrol. 2012; 23:948-958.
38. Li L, Khatri P, Sigdel TK, et al. A peripheral blood diagnostic test for acute rejection in renal transplantation. Am J Transplant. 2012;12: 2710-2718.
39. Ong S, Mannon RB. Genomic and proteomic fingerprints of acute rejection in peripheral blood and urine. Transplant Rev (Orlando). 2015; 29:60-67.
40. Zheng XX, Schachter AD, Vasconcellos L, et al. Increased CD40 ligand gene expression during human renal and murine islet allograft rejection. Transplantation. 1998;65:1512-1515.
41. Li B, Hartono C, Ding R, et al. Noninvasive diagnosis of renal-allograft rejection bymeasurement of messenger RNA for perforin and granzyme B in urine. N Engl JMed. 2001;344:947-954.
42. Ding R, Li B, Muthukumar T, et al. CD103 mRNA levels in urinary cells predict acute rejection of renal allografts. Transplantation. 2003;75: 1307-1312.
43. Tatapudi RR, Muthukumar T, Dadhania D, et al. Noninvasive detection of renal allograft inflammation by measurements of mRNA for IP-10 and CXCR3 in urine. Kidney Int. 2004;65:2390-2397.
44. Kotsch K, Mashreghi MF, Bold G, et al. Enhanced granulysin mRNA expression in urinary sediment in early and delayed acute renal allograft rejection. Transplantation. 2004;77:1866-1875.
45. Muthukumar T, Dadhania D, Ding R, et al. Messenger RNA for FOXP3 in the urine of renal-allograft recipients. N Engl J Med. 2005;353: 2342-2351.
46. Afaneh C, Muthukumar T, Lubetzky M, et al. Urinary cell levels of mRNA for OX40, OX40L, PD-1, PD-L1, or PD-L2 and acute rejection of human renal allografts. Transplantation. 2010;90:1381-1387.
47. Suthanthiran M, Schwartz JE, Ding R, et al. Urinary-cell mRNA profile and acute cellular rejection in kidney allografts. N Engl J Med. 2013; 369:20-31.
48. Hricik DE, Nickerson P, Formica RN, et al. Multicenter validation of urinary CXCL9 as a risk-stratifying biomarker for kidney transplant injury. Am J Transplant. 2013;13:2634-2644.
49. Matignon M, Ding R, Dadhania DM, et al. Urinary cell mRNA profiles and differential diagnosis of acute kidney graft dysfunction. J Am Soc Nephrol. 2014;25:1586-1597.
50. Keslar KS, Lin M, Zmijewska AA, et al. Multicenter evaluation of a standardized protocol for noninvasive gene expression profiling. Am J Transplant. 2013;13:1891-1897.
51. Khatri P, Roedder S, Kimura N, et al. A common rejection module (CRM) for acute rejection across multiple organs identifies novel therapeutics for organ transplantation. J ExpMed. 2013;210:2205-2221.
52. Li L, Khush K, Hsieh SC, et al. Identification of common blood gene signatures for the diagnosis of renal and cardiac acute allograft rejection. PLoS One. 2013;8:e82153.
53. Roedder S, Sigdel T, Salomonis N, et al. The kSORTassay to detect renal transplant patients at high risk for acute rejection: results of the multicenter AART study. PLoS Med. 2014;11:e1001759.
54. Dahan K, Audard V, Roudot-Thoraval F, et al. Renal allograft biopsies with borderline changes: predictive factors of clinical outcome. Am J Transplant. 2006;6:1725-1730.
55. HaasM, Sis B, Racusen LC, et al. Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant. 2014;14:272-283.
56. Halloran PF, Pereira AB, Chang J, et al. Microarray diagnosis of antibody-mediated rejection in kidney transplant biopsies: An international prospective study (INTERCOM). Am J Transplant. 2013; 13:2865-2874.
57. Perco P, Pleban C, Kainz A, et al. Gene expression and biomarkers in renal transplant ischemia reperfusion injury. Transpl Int. 2007;20:2-11.
58. Hauser P, Schwarz C, Mitterbauer C, et al. Genome-wide geneexpression patterns of donor kidney biopsies distinguish primary allograft function. Lab Invest. 2004;84:353-361.
59. Famulski KS, Broderick G, Einecke G, et al. Transcriptome analysis reveals heterogeneity in the injury response of kidney transplants. Am J Transplant. 2007;7:2483-2495.
60. Obeidat MA, Luyckx VA, Grebe SO, et al. Post-transplant nuclear renal scans correlate with renal injury biomarkers and early allograft outcomes. Nephrol Dial Transplant. 2011;26:3038-3045.
61. Nankivell BJ, Borrows RJ, Fung CL, et al. The natural history of chronic allograft nephropathy. N Engl JMed. 2003;349:2326-2333.
62. Nankivell BJ, Chapman JR. Chronic allograft nephropathy: current concepts and future directions. Transplantation. 2006;81:643-654.
63. El-Zoghby ZM, Stegall MD, Lager DJ, et al. Identifying specific causes of kidney allograft loss. Am J Transplant. 2009;9:527-535.
64. Einecke G, Sis B, Reeve J, et al. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant. 2009;9:2520-2531.
65. Naesens M, Kuypers DR, De Vusser K, et al. The histology of kidney transplant failure: A long-term follow-up study. Transplantation. 2014; 98:427-435.
66. Park WD, Griffin MD, Cornell LD, et al. Fibrosis with inflammation at one year predicts transplant functional decline. J Am Soc Nephrol. 2010;21: 1987-1997.
67. Torres IB, Moreso F, Sarro E, Meseguer A. The interplay between inflammation and fibrosis in kidney transplantation. Biomed Res Int. 2014; 2014:750602.
68. Scherer A, Gwinner W, Mengel M, et al. Transcriptome changes in renal allograft protocol biopsies at 3 months precede the onset of interstitial fibrosis/tubular atrophy (IF/TA) at 6 months. Nephrol Dial Transplant. 2009;24:2567-2575.
69. MengelM, Chang J, Kayser D, et al. Themolecular phenotype of 6-week protocol biopsies from human renal allografts: reflections of prior injury but not future course. Am J Transplant. 2011;11:708-718.
70. Naesens M, Khatri P, Li L, et al. Progressive histological damage in renal allografts is associated with expression of innate and adaptive immunity genes. Kidney Int. 2011;80:1364-1376.
71. Vitalone MJ, O'Connell PJ, Jimenez-Vera E, et al. Epithelial-tomesenchymal transition in early transplant tubulointerstitial damage. J Am Soc Nephrol. 2008;19:1571-1583.
72. VitaloneMJ, O'Connell PJ, WavamunnoM, et al. Transcriptome changes of chronic tubulointerstitial damage in early kidney transplantation. Transplantation. 2010;89:537-547.
73. Toki D, Zhang W, Hor KL, et al. The role of macrophages in the development of human renal allograft fibrosis in the first year after transplantation. Am J Transplant. 2014;14:2126-2136.
74. Menon MC, Chuang PY, Li Z, et al. Intronic locus determines SHROOM3 expression and potentiates renal allograft fibrosis. J Clin Invest. 2015; 125:208-221.
75. ParkWD, Stegall MD. A meta-analysis of kidney microarray datasets: investigation of cytokine gene detection and correlation with rt-PCR and detection thresholds. BMC Genomics. 2007;8:88.
76. Kong X, Mas V, Archer KJ. A non-parametric meta-analysis approach for combining independent microarray datasets: Application using two microarray datasets pertaining to chronic allograft nephropathy. BMC Genomics. 2008;9:98.
77. Saint-Mezard P, Berthier CC, Zhang H, et al. Analysis of independentmicroarray datasets of renal biopsies identifies a robust transcript signature of acute allograft rejection. Transpl Int. 2009;22:293-302.
78. Dosanjh A, Robison E, Mondala T, et al. Genomic meta-analysis of growth factor and integrin pathways in chronic kidney transplant injury. BMC Genomics. 2013;14:275.
79. Mas V, Maluf D, Archer K, et al. Establishing the molecular pathways involved in chronic allograft nephropathy for testing new noninvasive diagnostic markers. Transplantation. 2007;83:448-457.
80. Hotchkiss H, Chu TT, Hancock WW, et al. Differential expression of profibrotic and growth factors in chronic allograft nephropathy. Transplantation. 2006;81:342-349.
81. Anglicheau D, Muthukumar T, Hummel A, et al. Discovery and validation of a molecular signature for the noninvasive diagnosis of human renal allograft fibrosis. Transplantation. 2012;93:1136-1146.
82. Kurian SM, Heilman R, Mondala TS, et al. Biomarkers for early and late stage chronic allograft nephropathy by proteogenomic profiling of peripheral blood. PLoS One. 2009;4:e6212.
83. Nakorchevsky A, Hewel JA, Kurian SM, et al. Molecular mechanisms of chronic kidney transplant rejection via large-scale proteogenomic analysis of tissue biopsies. J Am Soc Nephrol. 2010;21:362-373.
84. Brouard S, Mansfield E, Braud C, et al. Identification of a peripheral blood transcriptional biomarker panel associatedwith operational renal allograft tolerance. Proc Natl Acad Sci U S A. 2007;104:15448-15453.
85. Brouard S, Le Bars A, Dufay A, et al. Identification of a gene expression profile associated with operational tolerance among a selected group of stable kidney transplant patients. Transpl Int. 2011;24:536-547.
86. Newell KA, Asare A, Kirk AD, et al. Identification of a B cell signature associated with renal transplant tolerance in humans. J Clin Invest. 2010; 120:1836-1847.
87. Sagoo P, Perucha E, Sawitzki B, et al. Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans. JClin Invest. 2010;120:1848-1861.
88. Baron D, Ramstein G, Chesneau M, et al. A common gene signature across multiple studies relate biomarkers and functional regulation in tolerance to renal allograft. Kidney Int. 2015;87:984-995.
89. Braud C, Baeten D, Giral M, et al. Immunosuppressive drug-free operational immune tolerance in human kidney transplant recipients: Part I. Blood gene expression statistical analysis. J Cell Biochem. 2008;103: 1681-1692.
90. Lozano JJ, Pallier A, Martinez-LlordellaM, et al. Comparison of transcriptional and blood cell-phenotypic markers between operationally tolerant liver and kidney recipients. Am J Transplant. 2011;11:1916-1926.
91. Quintana LF, Sole-Gonzalez A, Kalko SG, et al. Urine proteomics to detect biomarkers for chronic allograft dysfunction. J Am Soc Nephrol. 2009;20:428-435.
92. SrivastavaM, EidelmanO, Torosyan Y, et al. Elevated expression levels of ANXA11, integrins beta3 and alpha3, and TNF-alpha contribute to a candidate proteomic signature in urine for kidney allograft rejection. Proteomics Clin Appl. 2011;5:311-321.
93. Sigdel TK, Kaushal A, Gritsenko M, et al. Shotgun proteomics identifies proteins specific for acute renal transplant rejection. Proteomics Clin Appl. 2010;4:32-47.
94. Banon-Maneus E, Diekmann F, Carrascal M, et al. Two-dimensional difference gel electrophoresis urinary proteomic profile in the search of nonimmune chronic allograft dysfunction biomarkers. Transplantation. 2010; 89:548-558.
95. Wu D, Zhu D, Xu M, et al. Analysis of transcriptional factors and regulation networks in patients with acute renal allograft rejection. J Proteome Res. 2011;10:175-181.
96. Loftheim H, Midtvedt K, Hartmann A, et al. Urinary proteomic shotgun approach for identification of potential acute rejection biomarkers in renal transplant recipients. Transplant Res. 2012;1:9.
97. Sigdel TK, Salomonis N, Nicora CD, et al. The identification of novel potential injury mechanisms and candidate biomarkers in renal allograft rejection by quantitative proteomics. Mol Cell Proteomics. 2014;13: 621-631.
98. Freue GV, Sasaki M, Meredith A, et al. Proteomic signatures in plasma during early acute renal allograft rejection. Mol Cell Proteomics. 2010;9: 1954-1967.
99. O'Riordan E, Orlova TN, Mei JJ, et al. Bioinformatic analysis of the urine proteome of acute allograft rejection. J Am Soc Nephrol. 2004;15: 3240-3248.
100. Schaub S, Rush D, Wilkins J, et al. Proteomic-based detection of urine proteins associated with acute renal allograft rejection. J Am Soc Nephrol. 2004;15:219-227.
101. Schaub S, Wilkins JA, AntonoviciM, et al. Proteomic-based identification of cleaved urinary beta2-microglobulin as a potentialmarker for acute tubular injury in renal allografts. Am J Transplant. 2005;5:729-738.
102. Ling XB, Sigdel TK, Lau K, et al. Integrative urinary peptidomics in renal transplantation identifies biomarkers for acute rejection. J Am Soc Nephrol. 2010;21:646-653.
103. Scian MJ, Maluf DG, Mas VR. MiRNAs in kidney transplantation: potential role as new biomarkers. Expert Rev Mol Diagn. 2013;13:93-104.
104. Mas VR, Dumur CI, Scian MJ, et al. MicroRNAs as biomarkers in solid organ transplantation. Am J Transplant. 2013;13:11-19.
105. Sui W, Dai Y, Huang Y, et al. Microarray analysis of MicroRNA expression in acute rejection after renal transplantation. Transpl Immunol. 2008; 19:81-85.
106. Lorenzen JM, Volkmann I, Fiedler J, et al. Urinary miR-210 as a mediator of acute T-cellmediated rejection in renal allograft recipients. Am J Transplant. 2011;11:2221-2227.
107. Scian MJ, Maluf DG, David KG, et al. MicroRNA profiles in allograft tissues and paired urines associate with chronic allograft dysfunction with IF/TA. Am J Transplant. 2011;11:2110-2122.
108. Glowacki F, Savary G, Gnemmi V, et al. Increased circulating miR-21 levels are associated with kidney fibrosis. PLoS One. 2013;8:e58014.
109. Atzler D, Schwedhelm E, Zeller T. Integrated genomics and metabolomics in nephrology. Nephrol Dial Transplant. 2014;29:1467-1474.
110. Weiss RH, KimK. Metabolomics in the study of kidney diseases. Nat Rev Nephrol. 2012;8:22-33.
111. Bohra R, Klepacki J, Klawitter J, et al. Proteomics and metabolomics in renal transplantation-quo vadis Transpl Int. 2013;26:225-241.
112. Blydt-Hansen TD, Sharma A, Gibson IW, et al. Urinary metabolomics for noninvasive detection of borderline and acute Tcell-mediated rejection in children after kidney transplantation. Am J Transplant. 2014;14:2339-2349.
113. Wang JN, Zhou Y, Zhu TY, et al. Prediction of acute cellular renal allograft rejection by urinarymetabolomics usingMALDI-FTMS. J Proteome Res. 2008;7:3597-3601.
114. Zhao X, Chen J, Ye L, et al. Serum metabolomics study of the acute graft rejection in human renal transplantation based on liquid chromatographymass spectrometry. J Proteome Res. 2014;13:2659-2667.
115. Gourishankar S, Leduc R, Connett J, et al. Pathological and clinical characterization of the 'troubled transplant': data from the DeKAF study. Am J Transplant. 2010;10:324-330.